MASTERINVEST Kapitalanlage GmbH bought a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 38,103 shares of the company’s stock, valued at approximately $4,896,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Frazier Financial Advisors LLC acquired a new stake in shares of Merck KGaA in the 2nd quarter valued at $25,000. Rakuten Securities Inc. acquired a new position in Merck KGaA during the second quarter worth $27,000. Solstein Capital LLC bought a new position in Merck KGaA during the second quarter valued at about $33,000. Delos Wealth Advisors LLC bought a new position in Merck KGaA during the second quarter valued at about $33,000. Finally, Burk Holdings LLC acquired a new stake in shares of Merck KGaA in the second quarter worth about $39,000. Institutional investors own 0.10% of the company’s stock.
Merck KGaA Price Performance
Shares of OTCMKTS:MKGAF opened at $158.15 on Friday. The stock has a market capitalization of $20.44 billion, a P/E ratio of 24.14 and a beta of 0.96. The business has a 50-day moving average of $163.21 and a two-hundred day moving average of $148.95. Merck KGaA has a fifty-two week low of $116.68 and a fifty-two week high of $175.56. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Read More
- Five stocks we like better than Merck KGaA
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
